BSEInsider Trading / SAST1d ago · 24 Sept 2026, 06:12 pm
Pursuant to SEBI (PIT) Regulations, 2015 as amended and as per Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, the trading window for dealing in the securities of the Company shall remain closed for designated persons and their immediate relatives from Thursday, 01st October, 2026 till 48 hours after the date of Board Meeting wherein, inter-alia, the approval of Un-Audited Standalone and Consolidated Financial ....
Eiko Lifesciences Ltd · 540204
✦ AI SummaryResults
Eiko Lifesciences Ltd has announced the closure of its trading window for designated persons and their immediate relatives from October 1, 2026, until 48 hours after the Board Meeting where the Un-Audited Standalone and Consolidated Financial Results for the quarter ended September 30, 2026, will be considered.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Eiko Lifesciences Ltd - 540204 - Closure of Trading Window
Attachments (1)
📄pdf
Download →
b43c2669-ddfe-483c-bd36-5114266e6bde.pdf
View document text
Date: 24th September, 2026
Corporate Services Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
1st Floor, Dalal Street,
Fort, Mumbai – 400 001.
Scrip Code: 540204
Subject: Intimation Regarding the Closure of Trading Window
Dear Sir/ Ma'am,
Pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading)
Regulations, 2015 as amended and as per Company’s Code of Conduct for Regulating, Monitoring
and Reporting of Trading by Insiders (“Code”), the trading window for dealing in the securities of
the Company shall remain closed for designated persons and their immediate relatives from
Thursday, 01st October, 2026 till 48 hours after the date of Board Meeting wherein, inter-alia, the
approval of Un-Audited Standalone and Consolidated Financial Results for the quarter ended 30th
September, 2026 would be considered by the Board.
The date of the Board Meeting for consideration of the Un-Audited Financial Results of the
Company for the quarter ended 30th September, 2026 will be intimated separately in due course.
Accordingly, all Designated Persons and their immediate relatives are advised not to trade in the
securities of the company during the aforesaid trading window closure period.
This is for your information and records.
Yours Faithfully,
For Eiko Lifesciences Limited
Chintan Doshi
Company Secretary and Compliance Officer
Membership No: A36190
Eiko LifeSciences Limited CIN: L65993MH1977PLC258134
Registered Address: 604, Centrum, Opp. TMC Office, Near Satkar Grande Hotel, Wagle Estate, Thane MH 400604
Phone No.: +919082668855; Email id: investor.relations@eikolifesciences.com: website:www.eikolifesciences.com